ChiCTR2500097431 版本V1.0 版本创建时间2025/02/19 11:30:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500097431 

最近更新日期:

Date of Last Refreshed on:

2025-02-19 11:30:05 

注册时间:

Date of Registration:

2025-02-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

(109)低强度聚焦超声治疗肌筋膜疼痛综合症的临床疗效研究

Public title:

The effect of low intensity focused ultrasound on myofascial pain syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

低强度聚焦超声治疗肌筋膜疼痛综合症的临床疗效研究

Scientific title:

The effect of low intensity focused ultrasound on myofascial pain syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈泳佳 

研究负责人:

王谦 

Applicant:

Yongjia Chen 

Study leader:

Qian Wang 

申请注册联系人电话:

Applicant telephone:

+86 185 0281 6718

研究负责人电话:

Study leader's telephone:

+86 135 5180 7962

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

248625499@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wangqianwind@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

Guoxue Street 37,Wuhou District,Chengdu,Sichuan

Study leader's address:

Guoxue Street 37,Wuhou District,Chengdu,Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital,Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital,Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023年审(251)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee on Biomedical Research, West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-15 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Shaolin Deng

伦理委员会联系地址:

四川省成都市武侯区国学巷37号老八教412-413室

Contact Address of the ethic committee:

Room 412-413, Lao Ba Jiao, No.37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 3237

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital,Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

Guoxue Street 37,Wuhou District,Chengdu,Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

Guoxue Street 37,Wuhou District,Chengdu,Sichuan

经费或物资来源:

赞助商

Source(s) of funding:

Sponsor

Target disease:

Myofascial pain syndrome

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1. 主要目的:比较平面超声与低强度聚焦超声在抑制肌筋膜疼痛综合征触发点活性的临床效果。 2. 次要目的:探索低强度聚焦超声抑制肌筋膜疼痛综合征触发点活性状态的即时效应。  

Objectives of Study:

1. Main Objective: To compare the clinical efficacy of planar ultrasound and low-intensity focused ultrasound in inhibiting the activity of trigger points in myofascial pain syndrome. 2. Secondary objective: To explore the immediate effect of low intensity focused ultrasound on inhibiting the activation status of trigger points in myofascial pain syndrome.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.20~70 岁 2.符合《肌筋膜疼痛综合征的诊断与治疗》中关于 MPS 的诊断标准:满足 5 个主要标准和至少 1 个次要标准。

Inclusion criteria

1.20-70 years old; 2. Meet the diagnostic criteria for MPS in the Diagnosis and Treatment of Myofascial Pain Syndrome: meet 5 major criteria and at least 1 minor criterion

排除标准:

1.孕妇或备孕; 2.诊断为椎间盘突出症引起上肢/下肢放射性疼痛; 3.脊柱感染、骨折及肿瘤; 4.类风湿性关节炎、强直性脊柱炎活动期; 5.过去一年内曾接受干细胞等生物治疗; 6.1 个月内进行类固醇注射; 7.过去一年内服用全身免疫抑制药物; 8.过去 3 个月内服用抗风湿性疾病药物; 9.过去 3 个月内曾接受针刀治疗、中草药等治疗; 10.过去 2 周内曾接受针灸、拔罐等治疗; 11.合并心脑血管疾病,如心肌梗死、心衰、未控制的高血压(180/90 mmHg)、脑卒中、TIA、肾脏及肝脏等脏器衰竭等; 12.肺结核、艾滋病毒、肝炎和梅毒等传染病; 13.不明原因的发热>38.0℃; 14.在一年内参与药物及器械研究 15.正在参与诉讼; 16.酒精、药物滥用史; 17.中重度焦虑、抑郁等心理疾病 18.不理解普通话,不认识汉字

Exclusion criteria:

1. Pregnant women or those trying to become pregnant; 2.Radiation-induced pain in the upper/lower extremities due to disc herniation; 3.spinal infection, fracture and tumor; 4.Active period of rheumatoid arthritis and ankylosing spondylitis; 5.have received biological therapies such as stem cells in the past year; 6.Steroid injection within 1 month; 7.Taking systemic immunosuppressive drugs within the past year; 8.Taking anti-rheumatic drugs in the past 3 months; 9.Have received needle-knife therapy, Chinese herbal medicine and other treatments in the past 3 months; 10.Have received acupuncture, cupping and other treatments in the past 2 weeks; 11. Complicated cardiovascular and cerebrovascular diseases, such as myocardial infarction, heart failure, uncontrolled hypertension (180/90mmHg), stroke, TIA, kidney, liver and other organ failure, etc.; 12.Infectious diseases such as tuberculosis, HIV, hepatitis and syphilis; 13.unexplained fever > 38.0℃; 14.Participate in drug and device research within one year; 15.is participating in litigation; 16.A history of alcohol and drug abuse; 17.moderate to severe anxiety, depression and other mental illness; 18.Unable to understand Mandarin and Chinese characters.

研究实施时间:

Study execute time:

From 2025-03-01 00:00:00 To 2025-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-01 00:00:00 To 2025-05-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Trial group

Sample size:

干预措施:

低强度聚焦超声治疗

干预措施代码:

Intervention:

LIFU

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

非聚焦超声波治疗

干预措施代码:

Intervention:

Non-focused ultrasound therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

VAS疼痛评分

指标类型:

主要指标

Outcome:

VAS Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能学评估

指标类型:

次要指标

Outcome:

Functional evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

表面肌电图结果

指标类型:

次要指标

Outcome:

sEMG result

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇痛药物使用情况

指标类型:

次要指标

Outcome:

Analgesic drug use

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生情况

指标类型:

副作用指标

Outcome:

Occurrence of adverse events

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机随机数字法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number randomization method by conputer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share raw data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-02-19 11:30:05